P

Inventor

ECONOMIDES ARIS N

US49 patents
⚠️ This page may combine multiple inventors who share the name “ECONOMIDES ARIS N”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

REGENERON PHARMA

44 patents
US6586251B2Jul 1, 2003

Methods of modifying eukaryotic cells

REGENERON PHARMA505 citations99
US7205148B2Apr 17, 2007

Genome mutation by intron insertion into an embryonic stem cell genome

REGENERON PHARMA93 citations98
US5470952ANov 28, 1995

CNTF and IL-6 antagonists

REGENERON PHARMA47 citations96
US9708635B2Jul 18, 2017

Methods of making a nucleic acid encoding a human variable region

REGENERON PHARMA9 citations93
US9388446B2Jul 12, 2016

Methods of producing hybrid antibodies

REGENERON PHARMA6 citations93
US9371553B2Jun 21, 2016

Genetically modified mice that produce hybrid antibodies

REGENERON PHARMA6 citations93
US9353394B2May 31, 2016

Methods of producing hybrid antibodies

REGENERON PHARMA6 citations93
US8846402B2Sep 30, 2014

Method for genetically modifying isolated non-human mammalian cell by homologous recombination

REGENERON PHARMA17 citations93
US7473557B2Jan 6, 2009

Method for targeting transcriptionally active loci

REGENERON PHARMA33 citations92
US9510569B2Dec 6, 2016

Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation

REGENERON PHARMA12 citations91
US6610510B1Aug 26, 2003

Morphogenic proteins

REGENERON PHARMA20 citations91
US10640800B2May 5, 2020

Mice that produce hybrid antibodies

REGENERON PHARMA4 citations84
US10526630B2Jan 7, 2020

Genetically modified mice that produce hybrid antibodies

REGENERON PHARMA3 citations84
US10378037B2Aug 13, 2019

Methods of making a nucleic acid encoding a human variable region

REGENERON PHARMA3 citations84
US10378040B2Aug 13, 2019

Mice that produce hybrid antibodies

REGENERON PHARMA4 citations84
US10378038B2Aug 13, 2019

Mice that produce hybrid antibodies

REGENERON PHARMA3 citations84
US10378039B2Aug 13, 2019

Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locus

REGENERON PHARMA3 citations84
US10227625B2Mar 12, 2019

Methods of modifying eukaryotic cells

REGENERON PHARMA3 citations84
US9528136B2Dec 27, 2016

Methods of modifying eukaryotic cells

REGENERON PHARMA5 citations84
US9382567B2Jul 5, 2016

Methods of producing hybrid antibodies

REGENERON PHARMA3 citations84
US11578135B2Feb 14, 2023

Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof

REGENERON PHARMA8 citations82
US9999207B2Jun 19, 2018

Nucleic acid construct for making a genetically modified rodent with an inducible ACVR1 mutation that causes ectopic bone formation

REGENERON PHARMA6 citations82
US10377817B2Aug 13, 2019

Human antibodies to GREM1

REGENERON PHARMA7 citations81
US10584364B2Mar 10, 2020

Mice that produce hybrid antibodies

REGENERON PHARMA1 citations73
US10344299B2Jul 9, 2019

Compositions and methods for modifying cells

REGENERON PHARMA3 citations73
US10531648B2Jan 14, 2020

Conditional rodent Acvr1 mutant gene

REGENERON PHARMA1 citations71
US10470444B2Nov 12, 2019

Method for making a genetically modified mouse with an inducible ACVR1 mutation that causes ectopic bone formation

REGENERON PHARMA1 citations71
US10448621B2Oct 22, 2019

Rodent embryonic stem cell with conditional ACVR1 mutant alleles

REGENERON PHARMA1 citations71
US11419319B2Aug 23, 2022

Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formation

REGENERON PHARMA2 citations69
US11407822B2Aug 9, 2022

Treatment of fibrodysplasia ossificans progressiva

REGENERON PHARMA2 citations69
US10392633B2Aug 27, 2019

Multifunctional alleles

REGENERON PHARMA2 citations68
US7285532B2Oct 23, 2007

Therapeutic method for treating bone formation diseases

REGENERON PHARMA2 citations63
US10988776B2Apr 27, 2021

Methods of modifying genes in eukaryotic cells

REGENERON PHARMA0 citations62
US11730150B2Aug 22, 2023

Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

REGENERON PHARMA0 citations61
USRE49121EJul 5, 2022

Genetically modified mouse with an inducible ACVR1 gene with a mutant R206H exon 5 that has ectopic bone formation

REGENERON PHARMA0 citations61
US10548302B2Feb 4, 2020

Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

REGENERON PHARMA1 citations61
US11634480B2Apr 25, 2023

Human antibodies to GREM1

REGENERON PHARMA0 citations60
US12473574B2Nov 18, 2025

Methods for modifying a genome

REGENERON PHARMA0 citations58
US12089576B2Sep 17, 2024

Nucleic acids comprising a modified rodent activin a receptor type 1 (Acvr1) gene

REGENERON PHARMA0 citations58
US11319557B2May 3, 2022

Multifunctional alleles

REGENERON PHARMA1 citations58
US6846908B2Jan 25, 2005

DCR-5 bone affecting ligand

REGENERON PHARMA0 citations52
US6660499B1Dec 9, 2003

DCR5, a BMP-binding protein, and applications thereof

REGENERON PHARMA0 citations52
US7241739B2Jul 10, 2007

Morphogenic protein

REGENERON PHARMA0 citations51
US11945872B2Apr 2, 2024

Anti-ACVR1 antibodies and uses thereof

REGENERON PHARMA0 citations48

MURPHY ANDREW J

2 patents

ECONOMIDES ARIS N

2 patents

MARTIN JOEL H

1 patent